James L. Wittliff, PhD
Email Dr. James L. Wittliff
Address: Health Sciences Center,
Bldg A, Rm 604, School of Medicine, Louisville KY 40292
Express mail zip: 40202
PhD, 1967, The University of Texas
Research Professor of Surgery
Director, Institute for Molecular Diversity & Drug Design (IMD3)
Web site: Hormone Receptor Lab
Clinical Laboratory Licenses:Director, Hormone Receptor Laboratory, University of Louisville
Commonwealth of Kentucky (State License #200078)
Health Care Financing Administration (Federal License – CLIA #18D0648476)
Mechanisms and Applications of Steroid & Peptide Hormone Action in Disease
Biochemical Techniques & Concepts for Detection and Treatment of Cancer
Laser Capture Microdissection and Its Use in Proteomics & Genomics
Sarah A. Andres, B.S.
D. Alan Kerr II, B.A.
Traci L. Kruer, B.S.
Irina Smolenkova, M.D.
Huy T. Le, B.S.
Nicole L. Beneigh
Kimberly E. Spatola
Dr. Wittliff and his team in the Hormone Receptor Laboratory are investigating the mechanisms by which steroid and peptide hormones induce their target cells to synthesize gene products and regulate biological networks. The kinetic and molecular properties of specific binding proteins (receptors) for steroid and peptide hormones are studied with regard to their functional role in responsive organs such as breast, colon, lung, ovary, uterus and their carcinomas. For more than four decades, Dr. Wittliff’s research program has investigated the biological properties and cellular roles of estrogen and progestin receptors in human cancers with the goal of improving their diagnostics and treatment. This includes the actions of estrogen mimics that may act as Endocrine Disruptor Compounds (EDCs). The role of epidermal growth factor receptor and a related protein, which is the product of the c-erb B-2 oncogene, are also being evaluated in the carcinomas of these organs. Currently, Hormone Receptor Laboratory members are examining the genomics and proteomics of specific cell types isolated by the technology of laser capture microdissection to ascertain the relationship between gene and protein expression profiles in human carcinomas and clinical outcome. His research is directed toward the discovery and dissemination of new knowledge as well as the filing of patents for technology developments.
Wittliff, J.L., Kruer, T.L., Andres, S.A., Smolenkova, I.A. Molecular Signatures of Estrogen Receptor-Associated Genes in Breast Cancer Predict Clinical Outcome. Proceedings: Fifth Annual Symposium on Hormonal Carcinogenesis J. J. Li, S.A. Li, S. Mohla, H. Rochefort & T. Maudelone (Eds), Springer Science, pp. 349-357, 2008.
Kerr II, D.A., Eliason, J.F., Wittliff, J.L. Expression of Estrogen Receptors and Growth Factor Receptors in Non-Small Cell Lung Cancers (NSCLC) using Cells Procured by Laser Capture Microdissection (LCM). Proceedings: Fifth Annual Symposium on Hormonal Carcinogenesis J. J. Li, S.A. Li, S. Mohla, H. Rochefort & T. Maudelone (Eds), Springer Science, pp. 377-384, 2008.
Andres, S.A., Kerr II, D.A., Bumpus, S.B., Kruer, T.L. Thieman, J.W., Smolenkova, I.A., Wittliff, J.L. A Three-Tiered Approach for Calibration of a Biosensor to Detect Estrogen Mimics. Adv. Exp. Med. Biol. 614: 305-313, 2008.
Wittliff, J.L., Andres, S.A., Kerr II, D.A., Erb, J.L. Biosensors for Detecting Estrogen-like Molecules and Protein Biomarkers. Adv. Exp. Med. Biol. 614: 315-322, 2008.
Galande, A. K., Bramlett, K. S., Trent, J. O., Burris, T. P. Wittliff, J. L. Potent Inhibitors of LXXLL-Based Protein-Protein Interactions. ChemBioChem, 6:1991-1998, 2005.
Wittliff, J. L., Andres, S. A., Kerr II, D. A. Estrogens & Their Mimics, I-V. In: Encyclopedia of Toxicology, 2nd Edition, Vol. II, (Philip Wexler, Ed.) Elsevier Press., Burlington, MA, pp 244-262, 2005.
Lee, J. W., Weiner, R. S., Sailstad, J. M., Bowsher, R. R., Knuth, D. W., O’Brien, P. J., Fourcroy, J. L., Dixit, R., Pandite, L., Pietrusko, R. G., Soares, H. D., Quarmby, V., Vesterqvist, O. L., Potter, D. M., Wittliff, J. L., Fritche, H. A., O’Leary, T., Perlee, L., Kadam, S., Wagner, J. A. Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report. Pharm. Res. 22: 499-511, 2005.
Kerr II, D.A., Smolenkova, I.A., Smolenkov, A.S., Wittliff, J.L., Pressure Cycling Technology and Its Application in Steroid Receptor Extraction. J. Clin Ligand Assay. 27: 18-23, 2004.
Galande, A. K., Bramlett, K. S., Burris, T. P., Wittliff, J. L., Spatola, A. S. Thioether Side-Chain Cyclization for Helical Peptide Formation: Inhibitors of Estrogen receptor-Coactivator Interactions. J. Peptide Res. 63:297-302, 2004.
Leduc, A-M, Trent, J. O., Wittliff, J. L., Bramlett, K. S., Briggs, S. L., Chirgadze, N. Y., Wang, Y., Burris, T. P. and Spatola, A. F. Helix-Stabilized Cyclic Peptides as Selective Inhibitors of Steroid Receptor - Coactivator Interactions. Proc. Natl. Acad. Sci. U.S.A., 100:11273-11278, 2003.
Wittliff, J. L. and Erlander, M. G. Laser Capture Microdissection and its Applications in Genomics & Proteomics. In: Laser Capture Microscopy and Microdissection, P. Michael Conn (ed.), Vol. 356, Chapter 2, pp. 12-25, Academic Press/Elsevier Science, San Diego, CA, 2002.
Fleisher, M., Dnistrian, A.M., Sturgeon, C. M., and Wittliff, J. L. Practice Guidelines and Recommendations for Use of Tumor Markers in the Clinic. In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications, D. P. Diamandis, H. A. Fritsche, H. Lilja, D. W. Chan, M. K. Schwartz (eds.), AACC Press, Washington, D.C, pp. 33-63, 2002.
Selected Patents & Licenses:
Judith L. Erb, James G. Downward, IV, John R. Erb-Downward and James L. Wittliff. Methods and Apparatus for Measurement of the Effect of Test Compounds on Signal Transduction at the Level of Biological Receptors. United States Patent No: US 6, 300,082 B1, Issued: October 9, 2001.
Judith L. Erb, James G. Downward, IV, John R. Erb-Downward and James L. Wittliff. Methods and Apparatus for Measurement of the Effect of Test Compounds on Signal Transduction at the Level of Biological Receptors. United States Patent No: US 20,020,137,055, Issued: September 26, 2002.
Judith L. Erb, James G. Downward, IV, John R. Erb-Downward and James L. Wittliff. Methods and Apparatus for Measurement of the Effect of Test Compounds on Signal Transduction at the Level of Biological Receptors. United States Letters Patent No: US 6,962,808 November 8, 2005.
Mark G. Erlander; Ranelle C. Salunga; Kimberly Stecker and James L. Wittliff Quantitative Immunohistochemistry for Covalently Modified or Structurally Altered Proteins . United States Application No. 60/314697, Filing Date August 22, 2001.
Mark G. Erlander; Ranelle C. Salunga; Kimberly Stecker and James L. Wittliff Quantitative Immunohistochemistry (QIHC) . United States Application No. 10/080435, Filing Date February 22, 2002.
Mark G. Erlander, Xiao-Jun Ma, Wei Wang and James L. Wittliff. Breast Cancer Signatures, United States Patent Application No. 10/795092, Filing Date March 5, 2004.
Mark G. Erlander, Xiao-Jun Ma, Wei Wang and James L. Wittliff. Signatures of ER Status in Breast Cancer, United States Patent Application No. 10/794263, Filing Date March 4, 2004.
Mark G. Erlander, Xiao-Jun Ma, Wei Wang and James L. Wittliff. Breast Cancer Survival and Recurrence. United States Application No. 10/871869, Filing Date: June 18, 2004.
James L. Wittliff, Exclusive Technology License to Asterand, Inc., Detroit, MI, ULRF Research Disclosure 05036, Method for Creation and Maintenance of a Comprehensive Tumor Marker Database and Associated Biological Specimens for the Discovery of Cancer Diagnostics, Prognostics and Therapeutics, Executed October 28, 2005.
James L. Wittliff and Sarah A. Andres. Methods for Identifying an Increased Likelihood of Recurrence of Breast Cancer. International Patent Application No. PCT/US2008/006963, date of filing June 3, 2008.
James L. Wittliff, Technology License to Xceed Molecular Corp, Toronto, Canada, ULRF Research Disclosure 07048, Gene Expression Profiles Predicting Clinical Behavior of Breast Cancer. U.S. Provisional Patent Application No. 60/933,091, date of filing June 4, 2007 (James L. Wittliff & Sarah A. Andres).
James L. Wittliff and D. Alan Kerr II. Methods of Predicting Disease-Free and Overall Survival of Estrogen Receptor Positive Breast Cancer. U.S. Provisional Patent Application No. 61/105,297, date of filing October 14, 2008.